2.30

2.22% 0.05

Pre-market: 2.32 0.02 +0.87%

Century Therapeutics Inc (IPSC)

Overview News Price History Option Chain Financials Discussions Forecast

Century Therapeutics Inc stock is traded at $2.30, with a volume of 1.08M. It is up +2.22% in the last 24 hours and down -1.71% over the past month. Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.

Previous Close:

$2.25

Open:

$2.35

24h Volume:

1.08M

Relative Volume:

0.95

Market Cap:

$414.82M

Revenue:

$109.16M

Net Income/Loss:

$-107.78M

P/E Ratio:

-2.079

EPS:

-1.1063

Net Cash Flow:

$-95.45M

1W Performance:

+8.49%

1M Performance:

-1.71%

6M Performance:

+302.17%

1Y Performance:

+299.72%

1-Day Range:

$2.26

$2.39

1-Week Range:

$2.085

$2.39

52-Week Range:

$0.435

$3.04

Century Therapeutics Inc Stock (IPSC) Company Profile

Name

Century Therapeutics Inc

Sector

Healthcare (1104)

Industry

Biotechnology (621)

Phone

215-981-4000

Address

25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA

Employee

Twitter

Next Earnings Date

2026-05-21

Latest SEC Filings

IPSC's Discussions on Twitter

Compare IPSC vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IPSC Century Therapeutics Inc	2.30	414.82M	109.16M	-107.78M	-95.45M	-1.1063
VRTX Vertex Pharmaceuticals Inc	450.46	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.98	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	884.20	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	287.80	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	160.06	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-25-26	Initiated	TD Cowen	Buy
Aug-08-24	Initiated	Rodman & Renshaw	Buy
Aug-28-23	Downgrade	JP Morgan	Overweight → Neutral
Dec-27-22	Initiated	Chardan Capital Markets	Buy
Oct-31-22	Initiated	Guggenheim	Buy
Oct-10-22	Initiated	Canaccord Genuity	Buy
May-23-22	Initiated	H.C. Wainwright	Buy
May-12-22	Initiated	William Blair	Mkt Perform
Jul-13-21	Initiated	BofA Securities	Buy
Jul-13-21	Initiated	JP Morgan	Overweight
Jul-13-21	Initiated	Piper Sandler	Overweight

View All

Century Therapeutics Inc Stock (IPSC) Latest News

Jun 15, 2026

Century Therapeutics SVP Carr sells $3,691 in company stock By Investing.com - Investing.com Australia

Jun 15, 2026

Century Therapeutics executive Gregory Russotti sells $5,767 in stock By Investing.com - Investing.com India

Jun 15, 2026

Century Therapeutics (IPSC) executive sells shares to cover RSU tax withholding - Stock Titan

Jun 15, 2026

Tax-related share sale by Century Therapeutics (IPSC) SVP Carr - Stock Titan

Jun 15, 2026

Century Therapeutics (IPSC) CEO reports 13,849-share tax withholding on RSU vesting - Stock Titan

Jun 15, 2026

Century Therapeutics (IPSC) CSO reports tax withholding of shares and restated holdings - Stock Titan

Jun 15, 2026

Jun 13, 2026

Here's Why We're Watching Century Therapeutics' (NASDAQ:IPSC) Cash Burn Situation - Yahoo Finance

Jun 13, 2026

Jun 12, 2026

Century Therapeutics (IPSC) director Alessandro Riva granted 74,000 stock options - Stock Titan

Jun 12, 2026

Director Daphne Quimi receives 74,000 stock options at Century Therapeutics (NASDAQ: IPSC) - Stock Titan

Jun 12, 2026

Century Therapeutics (IPSC) director receives grant of 74,000 stock options - Stock Titan

Jun 12, 2026

Century Therapeutics (IPSC) director granted 74,000 stock options at $2.24 - Stock Titan

Jun 12, 2026

Century Therapeutics (IPSC) awards 74,000 stock options to director Kimberly Blackwell - Stock Titan

Jun 12, 2026

Century Therapeutics (IPSC) shareholders back higher authorized shares and board slate - Stock Titan

Jun 12, 2026

Insider sale notice for IPSC (NASDAQ: IPSC) — 2,584 shares planned; prior disposals listed - Stock Titan

Jun 12, 2026

Jun 10, 2026

Century Therapeutics (IPSC) Reports Positive Preclinical Results For Diabetes Cell Therapy CNTY-813 - Insider Monkey

Jun 10, 2026

Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight - GlobeNewswire Inc.

Jun 10, 2026

Jun 09, 2026

Mizuho Securities Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $8 - Moomoo

Jun 09, 2026

Century Therapeutics (IPSC) executive logs small automatic share sale for taxes - Stock Titan

Jun 09, 2026

Century Therapeutics (IPSC) SVP’s automatic 249-share sale covers RSU tax withholding - Stock Titan

Jun 09, 2026

Century Therapeutics (NASDAQ: IPSC) CEO has 463 shares withheld for RSU taxes - Stock Titan

Jun 09, 2026